Enoximone (INN, trade name Perfan) is an imidazolinone phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.
Medical uses
Enoximone produces haemodynamic improvement and a fall in pulmonary wedge pressure and vascular resistance. It is used as short-term treatment in acute decompensated heart failure and as a bridge to cardiac transplantation.
However a systematic review of oral phosphodiesterase 3 inhibitors in chronic heart failure, found that longer-term use of enoximone was associated with an increased risk of arrhythmia and mortality, which has limited its role to short-term, intravenous therapy rather than chronic oral treatment.
Pharmacology
Pharmacokinetics
Enoximone has an elimination half-life in the range of 4–10 hours with about 85% plasma protein binding.
Pharmacodynamics Enoximone is a imidazolone derivative that acts as a selective phosphodiesterase 3 (and, to a lesser extent, 4) inhibitor, raising intracellular cyclic AMP in cardiac and vascular smooth muscle to produce positive inotropic and vasodilator effects without significantly increasing cardiac oxygen demand.
References
External links